Schrodinger (NASDAQ:SDGR) Stock Jumps 8.1% - Time to Buy?

Schrodinger logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Schrödinger shares rose 8.1% in Wednesday mid-day trading to $27.75, while trading volume was 89% below its average.
  • The company beat quarterly estimates, reporting a loss of $0.50 per share versus analysts’ expected $0.67 loss and revenue of $64.49 million, up 18.7% year over year.
  • Analyst views were mixed: the consensus rating was “Hold,” with an average price target of $26.67. Insiders sold 87,204 shares worth about $2.8 million over the prior 90 days.
  • Interested in Schrodinger? Here are five stocks we like better.

Schrodinger, Inc. (NASDAQ:SDGR - Get Free Report)'s stock price shot up 8.1% during mid-day trading on Wednesday. The company traded as high as $27.58 and last traded at $27.75. 165,544 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 1,545,371 shares. The stock had previously closed at $25.66.

Wall Street Analyst Weigh In

SDGR has been the subject of a number of analyst reports. KeyCorp upped their price objective on Schrodinger from $20.00 to $32.00 and gave the stock an "overweight" rating in a research note on Friday, October 16th. BMO Capital Markets lifted their target price on Schrodinger from $24.00 to $30.00 and gave the company an "outperform" rating in a research note on Monday, October 12th. Weiss Ratings raised shares of Schrodinger from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 27th. TD Cowen raised their price target on shares of Schrodinger from $31.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Finally, Zacks Research cut shares of Schrodinger from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 3rd. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $26.67.

Read Our Latest Analysis on Schrodinger

Schrodinger Trading Up 5.6%

The company has a market cap of $2.03 billion, a PE ratio of -34.59 and a beta of 1.69. The firm's 50-day simple moving average is $27.18 and its two-hundred day simple moving average is $17.59.

Schrodinger (NASDAQ:SDGR - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.17. Schrodinger had a negative net margin of 22.02% and a negative return on equity of 18.12%. The business had revenue of $64.49 million during the quarter, compared to analysts' expectations of $47.73 million. During the same quarter last year, the company posted ($0.45) earnings per share. The business's quarterly revenue was up 18.7% on a year-over-year basis. As a group, analysts predict that Schrodinger, Inc. will post -1.39 EPS for the current year.

Insider Buying and Selling

In other Schrodinger news, insider Karen Akinsanya sold 31,599 shares of Schrodinger stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $29.37, for a total transaction of $928,062.63. Following the completion of the sale, the insider owned 69,956 shares of the company's stock, valued at approximately $2,054,607.72. The trade was a 31.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Abel sold 23,605 shares of the business's stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $34.00, for a total value of $802,570.00. Following the sale, the insider owned 54,219 shares in the company, valued at approximately $1,843,446. The trade was a 30.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 87,204 shares of company stock worth $2,781,833 in the last 90 days. Insiders own 10.10% of the company's stock.

Hedge Funds Weigh In On Schrodinger

A number of institutional investors have recently bought and sold shares of SDGR. BlackRock Inc. acquired a new stake in Schrodinger in the 2nd quarter valued at $170,978,000. Rubric Capital Management LP lifted its holdings in Schrodinger by 43.8% during the first quarter. Rubric Capital Management LP now owns 6,000,000 shares of the company's stock valued at $68,160,000 after purchasing an additional 1,828,502 shares in the last quarter. Amova Asset Management Americas Inc. lifted its holdings in Schrodinger by 13.2% during the first quarter. Amova Asset Management Americas Inc. now owns 3,190,837 shares of the company's stock valued at $36,248,000 after purchasing an additional 371,167 shares in the last quarter. Public Sector Pension Investment Board lifted its holdings in Schrodinger by 79.0% during the third quarter. Public Sector Pension Investment Board now owns 350,738 shares of the company's stock valued at $10,890,000 after purchasing an additional 154,824 shares in the last quarter. Finally, Edgestream Partners L.P. acquired a new stake in shares of Schrodinger in the third quarter valued at about $5,271,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Schrodinger Company Profile

(Get Free Report)

Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company's tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Schrodinger Right Now?

Before you consider Schrodinger, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Schrodinger wasn't on the list.

While Schrodinger currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines